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Men having sex with men (MSM) are by far the transmission-risk-category most affected by HIV in Berlin 
and were investigated in this pilot-study with the aim to identify detailed risk- and prevention-
behaviours in recently infected persons. From November, 2005 - February, 2007, venous blood samples 
were taken from patients in Berlin aged 18 years within 3 months after diagnosis of HIV-infection and 
tested with BED IgG-capture-ELISA (BED-CEIA) to differentiate between longstanding and recent HIV-
infections dating back no longer than 140 days from blood sampling. Data on knowledge, attitudes, 
behaviour and practices (“KABP-survey”) relating to HIV/AIDS, were collected anonymously by 
structured patients’ questionnaires, accomplished by demographic data via additional questionnaires 
filled by the physicians. SPSS 15.0 was used for data analysis. This sub-analysis includes 37 MSM with 
confirmed recently acquired HIV infection. Mean age was 34 years (20 - 53). Good knowledge on 
HIV/AIDS in Germany and transmission risks was present in most cases; nevertheless unprotected 
sexual contacts were indicated by 90% of recently HIV-infected MSM (independent from type of 
intercourse and partners’ sero-status) with 64% reporting unprotected anal intercourse. Unprotected 
anal intercourse with a person they knew to be infected with HIV was stated by 19% of cases. In 5% 
drugs/alcohol and in 48% (n = 18/37) uncertain HIV-related knowledge, hope and beliefs about 
transmission risks were stated as reasons for unprotected sex. Almost half of recently infected MSM in 
this pilot-study were infected because hope and beliefs on HIV-transmission-risks had guided their 
personal decisions on HIV-prevention efforts. Limitations due to a small study population, lack of HIV-
negative-tested controls and selection bias should be optimised in future studies; however, the findings 
have strong implications for amending prevention messages in Germany addressing MSM. 
 





HIV/AIDS surveillance in Germany is based on obligatory 
anonymous reporting of newly diagnosed HIV infections 
from laboratories diagnosing HIV infections in blood 
samples, whereas AIDS cases and HIV/AIDS-related 
mortality are reported voluntarily to the Robert Koch-
Institute (RKI) from treating physicians. HIV case report-
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surveillance in Germany is legally regulated through of 
the national Protection against Infection Act 
(Infektionsschutzgesetz; IfSG). HIV case reporting 
includes a case-related coding with the aim to identify 
double or multiple case reports thus improving data 
quality considerably without allowing at the same time to 
make individuals identifiable (Hamouda, 2003). HIV 
surveillance in Germany observed a steady decline of 
reported newly diagnosed HIV cases since the mid 19- 
nineties with the lowest annual number of 1,443 cases 






ble resurgence of newly diagnosed cases by more than 
90% until 2007 when 2,752 annual cases were reported. 
This increase was primarily related to the transmission 
risk category men having sex with men (MSM) (Hamouda 
et al., 2007; RKI, 2008). The rise observed in MSM, 
however, is not yet fully understood since traditional 
surveillance data only allow limited risk analyses. First 
data from HIV recency testing in Germany suggest that 
this increase is not only due to more frequent HIV 
diagnoses, but rather new infections actually happen 
more often, especially in the age group 20 - 29 years 
(Bätzing-Feigenbaum et al., 2009). An internet survey in 
2006 addressing MSM in Germany found indicators for 
sexual behaviour implying increasing risk to acquire HIV 
(Schmidt et al., 2007). 
It is the specific nature of HIV, its natural course of 
infection and its particular epidemiology which implicate 
limitations with regards to the interpretation of traditional 
surveillance data. One limitation is that the newly diag-
nosed HIV cases represent only part of the actually newly 
acquired, incident infections, because not all new HIV 
infections are diagnosed immediately. The main reasons 
are the frequent lack of symptoms during acute HIV 
infection, the unspecific character of symptoms, and the 
extreme variability of the asymptomatic period until 
symptoms are observed which can last up to many years 
(Kahn and Walker, 1998). Another limitation is that the 
available tools for routine HIV diagnosis only allow to 
confirming diagnosis, but for the most part not to deciding 
when the infection actually happened. Only under the 
rare condition that the infection is diagnosed during acute 
infection presenting markers for acute seroconversion the 
time of infection can be determined with some accuracy 
(Daar et al., 2001). 
It was a diagnostic cornerstone when in 1998 a 
serology-based algorithm was described that was able to 
discriminate between recent and longstanding HIV 
infections (Janssen et al., 1998). Since then the 
methodology was further developed and amended by a 
number of working groups with test systems based on 
various approaches and algorithms (Suligoi et al., 2003; 
Murphy et al., 2003; Dobbs et al., 2004; Barin et al., 
2005; Martro et al., 2005; Parekh and McDougal, 2005; 
Schüpbach et al., 2007). Due to the relatively low speci-
ficity and sensitivity of all methods published until today, 
these tests are approved for epidemiological research 
only and not for individual diagnosis. In a pilot study 
between 2005 and 2007 in Berlin the methodology was 
used for the first time in Germany. In the first phase we 
compared two distinct methods using a sample of 148 
HIV seroconverters from the German HIV Seroconverter 
Cohort with well defined dates of seroconversion 
(Loschen et al., 2008). Both, the BED IgG-capture ELISA 
(BED-CEIA) and the Avidity-Test proved competent to 
differentiate between recent HIV infections dating back 
no longer than 140 days from blood sampling and long-
standing infections. In the  second  phase  we  tested  the 




BED-CEIA in the field by implementing a pilot study with 
cross-sectional recruitment of patients with newly 
diagnosed HIV infections in Berlin. 
In the Berlin pilot study the proportion of recently 
acquired HIV infections in the study population of overall 
51% (Bätzing-Feigenbaum at al., 2009) was high 
compared with findings from other studies in neighbour-
ing countries, where proportions of 27% in Austria, 36% 
in Switzerland, and 25% in France were found 
(Puchlhammer-Stockl et al., 2005; Gebhardt et al., 2007; 
Lot et al., 2004). But the results referring to MSM in the 
French national HIV surveillance indicating a proportion 
of 46% (Semaille et al., 2007) were comparable with the 
corresponding proportion found in the Berlin study (54%). 
The low proportion of recent infections in persons with 
HIV transmission risks other than MSM of 16% in the pilot 
study corresponded well with the findings from France 
were 18% of cases with heterosexual transmission risk 
and 10% of persons originating from HIV high prevalence 
countries (HPC) in sub-Saharan Africa were found to 
have recent HIV infections (Semaille et al., 2007). The 
World Health Organisation (WHO) and the United 
Nations Programme on HIV/AIDS (UNAIDS) define HPC 
with an HIV prevalence higher than 1% in the general 
population (UNAIDS and WHO, 2008; UNAIDS, 2007). 
Methods to estimate recency or incidence of HIV 
infections are currently used as routine HIV surveillance 
instrument in some federal states and regions of the 
United States of America (CDC, 2006; Hall et al., 2008) 
and in the national HIV surveillance systems of France 
(Lot et al., 2004; Semaille et al., 2007) and Switzerland 
(Gebhardt et al., 2007). 
Since 2002 WHO and UNAIDS have advocated to 
supplement the traditional HIV core surveillance focusing 
on epidemiological and demographic data with the 
collection of data on knowledge, attitudes, behaviour and 
practices in the context of HIV/AIDS (“KABP”-survey), 
also referred to as “second generation surveillance” 
(WHO and UNAIDS, 2002). The aim of collecting such 
data is on the one hand to characterize sexual behaviour 
and practices including risks to acquire HIV infection, on 
the other hand to identify possible protective factors. Due 
to the constraints for HIV surveillance described above 
the realization of HIV second generation surveillance in 
Germany is limited and more or less restricted to sentinel 
surveillance sites or to selected study populations at 
increased risk for HIV. 
However, simple serological methods to identify the 
actual time window for recent HIV infections could open 
up new vistas on second generation surveillance. Thus 
case-related behavioural data can be correlated exactly 
to the individuals who recently acquired their HIV 
infection. To our knowledge KABP-data correlated with 
HIV recency test results were only used in the national 
HIV surveillance in Switzerland (Gebhardt et al., 2007). 
In Germany estimations of HIV incidence up to now 
have been limited to  the  back-calculation  modelling HIV 
 




case reports and prevalence data collected through the 
national HIV surveillance instruments (Hamouda et al., 
2007; RKI, 2008). There are currently no instruments of 
second generation HIV surveillance routinely implemen-
ted in Germany as recommended by the WHO and 
UNAIDS (WHO and UNAIDS, 2002). 
The aims and objectives of this study were to pilot the 
following questions: (i) to evaluate and establish 
serology-based algorithms for HIV recency testing in 
Germany (published elsewhere; Loschen et al., 2008); (ii) 
to judge feasibility and applicability of the method in the 
context of German HIV surveillance (published 
elsewhere; Bätzing-Feigenbaum et al., 2008; Bätzing-
Feigenbaum et al. 2009); (iii) to assess the relevance of 
the results for amending the German national HIV/AIDS 
surveillance in accordance with WHO standards 
(published elsewhere; Bätzing-Feigenbaum et al. 2008); 
(iv) to assess the collection of KABP-data related to 
HIV/AIDS and correlate these data with core epidemio-
logical information sampled from men having sex with 
men (MSM) recently infected with HIV (“second 
generation surveillance” in its strict sense according to 
WHO and UNAIDS). 
In this paper we address the last of the above 
mentioned aims. For several reasons we included only 
MSM with recently acquired HIV infection in the analysis. 
One reason is that the number of patients with other HIV 
transmission risk categories in this pilot study, were by far 
too small for sound analyses (13 of 132 patients 
recruited; Bätzing-Feigenbaum et al., 2009). This fact 
reflects on the other hand the situation in the Federal 
Land of Berlin, where MSM are the most affected 
transmission risk category for acquiring HIV infection. In 
2007 MSM constituted 77% of all new HIV diagnoses in 
Berlin compared with 56% in Germany country-wide 
(RKI, 2008). The focus on MSM is furthermore relevant 
from the Public Health point of view, since in contrast to 
all other transmission risk categories the number of reported 






Venous blood samples (VBS) were taken from patients not later 
than 3 months after an HIV infection has been diagnosed through 
HIV-1&2 ELISA screening followed by confirmatory Western Blood 
and/or PCR testing. VBS were sent within 48 hours to the RKI 
laboratory facilities where blood was processed and stored frozen 
in aliquots at -70°C until use. Samples were tested using a 
commercially available HIV-1 specific IgG capture ELISA (BED-
CEIA; Calypte Biomedical Corp., Lake Oswego, USA) (Dobbs et al., 
2004; Parekh et al., 2002; McDougal et al., 2006). The evaluation 
and establishment of the test at the RKI laboratory were published 
elsewhere (Loschen et al., 2008). 
The test showed acceptable sensitivity and specificity (80 and 
86% respectively) which were similar to the values published 
earlier(Parekh et al., 2002). To increase the probability of BED-
CEIA results to identify recent HIV infections we applied a lower 
cut-off for the normalized optical density (ODn) of 0.65. This 





and 93.6%, respectively (reduced sensitivity 45%). 
Thus all samples identified as ‘recent’ could be considered with 
high probability to represent a recently acquired HIV infection, while 
accepting at the same time a reduced sensitivity (Loschen et al., 
2008; Bätzing-Feigenbaum et al., 2009). In a next step the samples 
with BED-CEIA result “recent” were linked with the corresponding 





For long term storage, the samples were frozen at -20°C or colder, 
with care taken to avoid freezing and thawing specimens no more 
than 4 times. In the European Centre for the Epidemiological 
Monitoring of AIDS (EuroHIV) collaboration project (EuroHIV 
Incidence Collaboration, Work Package 7 (Murphy et al., 2008) part 
of the samples were additionally tested by at least one other 
laboratory: at the (i) Health Protection Agency, Centre for Infections, 
61 Colindale Avenue, London, NW9 5HT, UK; and at the (ii) Centre 
National de Référence du VIH, Centre Hopitalier Universitaire 
Bretonneau, 37044 Tours Cedex, France. 
For the BED-CEIA control testing plasma from the samples 
collected in the pilot study was thawed and aliquots were sent at 
standard refrigeration temperature (2 - 8°C) to the collaborative 
laboratories in the UK and France. BED-CEIA was applied 
according to standard protocols. 
Thirty one of thirty seven samples (84%) were sent to 
collaborative laboratories for additional quality control tests. The 
BED-CEIA results were confirmed for all thirty one samples as 
recently acquired HIV infections. 
 
 
Data collection and description of the sub-sample for analysis 
 
Cases were enrolled between November 1st, 2005 and February 
28th, 2007 through convenience sampling in private practices and 
outpatient clinics in the study area of Berlin, Germany, when 
patients were seeking medical care to request HIV counselling and 
testing. There are close to 50 centres specialized in HIV/AIDS in 
the Federal Land of Berlin and all were asked to participate. 20 of 
the 50 centres recruited at least one patient. Of the 20 collaborating 
centres, four are outpatient clinics and 16 are private practitioners. 
The data collection process has been described in detail previously 
(Bätzing-Feigenbaum et al., 2009). 
Inclusion criteria for patient recruitment were: (i) age 18 years or 
older; (ii) newly diagnosed HIV infection and time of venous blood 
sampling within 3 months from date of diagnosis; (iii) at time of 
blood sampling no clinically advanced AIDS disease (clinically 
stage C); and (iv) no antiretroviral treatment (ART) at time of blood 
sampling (Bätzing-Feigenbaum et al., 2009). 
Eligible patients were informed by the study physicians orally and 
through a study information form. Participants were only recruited 
after giving written informed consent. Physicians contributed basic 
clinical and medical history data filling in a structured questionnaire 
(“physicians’ questionnaire”) (Bätzing-Feigenbaum et al., 2009). 
Patients were asked to fill in a structured questionnaire (“patients’ 
questionnaire”) targeting on individual demographic data and 
KABP-data relating to HIV/AIDS. The patients’ questionnaire 
included the following items: 
 
- Individual behaviour regarding measures to prevent HIV 
transmission during six months before HIV diagnosis (11 
questions);  
- Assessment of personal risks for acquiring HIV during six months 
before HIV diagnosis (10 questions); 
- General assessment  of  HIV  transmission  routes  (11 questions); 
- Additional demographic data (2 questions); 
- General and  specific  knowledge  about  HIV/AIDS  (6 questions); 
 




Table 1. Comparison of basic demographic data (age group; country of origin) between the pilot study population 
(transmission risk category 'men having sex with men', MSM; with recently acquired HIV infection) [n = 37] and the data 
from newly diagnosed HIV infections in MSM reported in the national HIV surveillance system [n = 341] (Federal Land of 
Berlin; November 1, 2005 - February 28, 2007). 
 
Comparative variables HIV incidence pilot study 
[n = 37] 
National HIV 
surveillance  [n = 341] 
n valid % n % valid % 
Age group 20 - 29 years 12 32.4 95  27.9 
30 - 44 years 23 62.2 186 54.5 
> 44 years 2 5.4 60 17.6 
Country of origin Germany 35 94.6 268 78.8 89.3 
foreign origin 2 5.4 32 9.4 10.7 
total with valid data on origin 37 100.0 300 88.2 100.0 
unknown country of origin 0 0.0 41 11.8  




And - Sources of information about HIV/AIDS in the past 6 months 
(3 questions).  
All data were collected anonymously and unlinked not allowing to 
identifying patients’ identities retrospectively or prospectively. 
Participating physicians were paid an expense allowance per 
recruited case. Eligible patients were not offered any material 
compensation. However, physicians were allowed to pass on the 
allowance they received to the respective patient if they liked to do 
so. 
The study population has been described previously (Bätzing-
Feigenbaum et al. 2009). A total of 132 patients with newly 
diagnosed HIV infection were recruited. Of these 114 cases were 
eligible according to the predefined eligibility criteria. 102 of these 
specified MSM as HIV transmission risk category (89%), only 12 
cases belonged to other transmission risk categories. BED-CEIA 
results of the 102 MSM blood samples revealed that at time of 
diagnosis 53 patients had recent and 49 patients had longstanding 
HIV infections. The BED-CEIA results were highly specific (ODn  
0.65; high specificity defined with 97.6% that the HIV infection was 
acquired recently within the past 140 days before diagnosis) for 42 
patients, whilst 11 had a BED-CEIA result in the “grey zone” with 
lower specificity (Bätzing-Feigenbaum et al., 2009). For 37 of the 42 
MSM with highly specific BED-CEIA test result to be recently infected 
with HIV, patients’ questionnaires with corresponding KABP-data were 
available. Thus data from 37 MSM with recently acquired HIV infection 
are eligible for this sub-analysis aiming to evaluate the use of 





Analyses were performed using SPSS 15.0 (SPSS Inc. 
Headquarters, Chicago, Illinois 60606, USA). Means of metric 
variables were analysed creating ANOVA tables. KABP-data from 





The mean age of the study population was close to 34 
years (range: 20, 53 years; s = 8.18). The age group 30 - 
44 years prevailed with 62% (n = 23; Table 1). 35 
participants stated Germany as country of origin where 
they spent most part of their life, whereas only two cases 
indicated foreign origin. The national German HIV surveil-
lance at the RKI provided data from newly diagnosed HIV 
infections in MSM reported from the Federal Land of 
Berlin during the recruitment period (November, 2005 - 
February, 2007); however, information about the recency 
of the HIV infection is not available from this data source 
(RKI, 2008). Comparing these data with the study 
population (MSM with recently acquired HIV infection 
enrolled in private practices and outpatient clinics in 
Berlin) reveals that the study population is younger by 
mean of age (33.9 years and 35.3 years, respectively), 
the age group >44 years is less frequent (5% compared 
with 18%), and German origin is reported more often 
(Table 1).The education level of the study population of 
MSM from Berlin recently infected with HIV (n=37) was 
relatively high: 12 (32%) had a university examination 
degree as highest degree, 10 (27%) a university-entrance 
diploma, 8 (22%) a Q-level degree, and 6 (16%) an 
elementary school degree. 
The knowledge on HIV/AIDS in Germany was present 
in a large proportion of the study population. 84% knew 
that HIV cases increased in Germany in the past years; 
nearly 60% estimated the number of newly diagnosed 
HIV cases per year in Germany well between 1,000 and 
5,000 cases; and 40% estimated the total number of all HIV 
infections until  end of the year 2005 correctly between 
10,000 and 100,000 cases (data not shown). 70% did not 
agree with the statement that it is not that bad to be 
infected with HIV because there are new treatments 
available (however, 11% agreed with this statement) and 
81% did not confirm that they protected themselves less 
properly due to new antiretroviral therapies (only 3% 
agreed with this statement). 95% did not approve that 
highly active antiretroviral treatment (HAART) can cure 
HIV/AIDS and 84% disagreed with HAART to prevent 
transmission of HIV. However, 87% confirmed that 
HAART   can   extent   life   time   of   people   living   with 
 




Table 2. Assessment of various HIV transmission risks by MSM with recently acquired HIV infection (Federal Land of Berlin; November 
1 2005 - February 28 2007) [n = 37]. 
 
Possible risk for HIV transmission     [n = 37] Estimated risk level 
High Medium Low No risk Don't know Not spec. 
n % n % n % n % n % n % 
Toilette use 1 2.7 0 0.0 3 8.1 29 78.4 3 8.1 1 2.7 
Everyday life contacts 0 0.0 1 2.7 4 10.8 31 83.8 0 0.0 1 2.7 
Blood contact with intact skin 11 29.7 7 18.9 6 16.2 9 24.3 1 2.7 3 8.1 
Pregnancy 21 56.8 10 27.0 0 0.0 0 0.0 4 10.8 2 5.4 
Needle sharing 35 94.6 0 0.0 0 0.0 0 0.0 1 2.7 1 2.7 
Oral sex with ejaculation 27 73.0 6 16.2 2 5.4 0 0.0 1 2.7 1 2.7 
Oral sex without ejaculation 9 24.3 10 27.0 13 35.1 3 8.1 1 2.7 1 2.7 
Oral sex with an HIV-infected receptive partner 8 21.6 5 13.5 15 40.5 4 10.8 3 8.1 2 5.4 
Receptive sex (anal or vaginal) with ejaculation 36 97.3 0 0.0 0 0.0 0 0.0 0 0.0 1 2.7 
Receptive sex (anal or vaginal) without ejaculation 19 51.4 16 43.2 1 2.7 0 0.0 0 0.0 1 2.7 
Penetrating sex (anal or vaginal) with an HIV-
infected partner 




HIV/AIDS (PLWHA) considerably. 
In the past six months before diagnosis of their HIV 
infection 14% of the study cases informed themselves 
regularly about HIV/AIDS, 57% occasionally and 24 % 
did not confirm having informed themselves about 
HIV/AIDS. Sources of information perceived in the past 6 
months before diagnosis were posters (87%), advertise-
ment in journals (81%), information through gay press 
(81%), information in television spots (60%), internet 
(49%), cinema spots (46%), and flyers from AIDS 
counselling organisations (43%). Radio spots and public 
events or presentations were states less frequently. 
As most important sources of information about 
HIV/AIDS from a general point of view 78% of the study 
population stated conversation with friends and partners, 
Internet (76%), television (70%), daily newspapers (62%), 
“scene” journals (57%), and periodicals (51%), whereas 
other media like Public Health services, clinics, medical 
books, public speeches and events, radio and other sources 
were ranked as less important (data not shown). 
Table 2 shows the answers concerning a number of 
sexual and non-sexual HIV transmission risks for HIV as 
assessed by the study participants. Concerning sexual 
transmission risks 97% estimated the risk for HIV 
transmission as high through passive anal intercourse with 
ejaculation and 51% without ejaculation. Oral sex with 
ejaculation was perceived as high risk for the passive 
partner by 73%, without ejaculation only by 24%. 57% 
thought active, penetrating sex with an HIV infected 
partner implied high transmission risk, 43% stated only a 
medium risk. Daily life contacts were estimated to have 
low or no risk by the majority of participants. 95% an-
swered that 	
 has a high HIV transmission 
risk Table 3 summarizes information about current living 
arrangements, partnership characteristics, and path, 
source of infection and country where the HIV infection 
happened. 51% live as singles and 35% in a homosexual 
partnership. 9 of 13 MSM with a steady partner stated that 
they have sex outside this partnership. 70% stated that 
they know where they acquired their HIV infection, and 
46% said that they know the source personally. 46% 
indicated anonymous sexual contacts as transmission 
path (not including contacts with commercial sex 
workers). 16% acquired HIV infection through sex with 
their partner, 14% with a friend, and 8% in the context of 
a new relation. 95% acquired their HIV infection in 
Germany. 14% answered to know quite well and 79% 
supposedly the exact period when the HIV infection 
happened. 68% correlated the time when the HIV 
infection happened well within a period of 140 days 
before diagnosis (Table 3). 
Table 4 displays the sexual risks taken in the past six 
months before diagnosis as indicated by the participants. 
Furthermore the number of personal sexual contacts and the 
relative frequencies of protection through condom use during 
different sexual practices in the past six months before the 
HIV infection was diagnosed are shown. 92% of the recently 
infected MSM answered that they had unprotected sexual 
contacts in the last six months before diagnosis, without 
taking into consideration the type of sexual intercourse 
(oral, anal and/or vaginal sex) and the HIV-serostatus of 
their sexual partners. 51% had active and 51% had 
passive unprotected anal intercourse, these proportions 
not completely overlapping making a total of 64% 
unprotected anal intercourse including active, passive or 
both types. Totally 82% had unprotected oral intercourse 
(70% penetrative and 16% receptive).19% stated unpro-
tected anal intercourse with a person they knew to be 
infected with HIV (16% had penetrative and 11% 
receptive anal intercourse). 
Another complex of questions asked, whether or not, 
and how consistent the participants used condoms during 
 




Table 3. Partnership characteristics and information regarding path, source, and country of HIV acquisition in MSM with recently acquired HIV 
infection (Federal Land of Berlin; November 1 2005 - February 28 2007) [n = 37]. 
 
Question$             [n = 37] n     %           n        %            n % n % n % n  % 




Heterosexual Partnership Othe$r 
type 
   Not specified  
19 51.4 13 35.1 1 2.7 1 2.7        3 8.1  
(2) Steady partnership?  No Yes  Not specified  
23 62.2 13 35.1       1 2.7  
(3) If applicable, duration 
of partnership? 
2 - 6 
Months 
7 - 12 Months > 12 months   Not applicable 
4 10.8 1 2.7 9 24.3  23 62.2 
(4) If applicable, sex 
outside of steady 
partnership? 
No Yes  Not specified Not applicable 
4 10.8 9 24.3      1 2.7 23 62.2 
(5) Known source of 
infection? 
Yes, known Supposedly  Not specified  
26 70.3 9 24.3     2 5.4  
(8) Source of infection 
known personally? 
Yes, known no  Not specified  
17 45.9 15 40.5    5 13.5  






with steady partner 




in a new 
relation 
Not specified Multiple sexual 
transmission 
paths 
    
17 45.9 6 16.2 5 13.5 3 8.1   5 13.5 1 2.7 
(7) Country where infection 
happened? 
Germany Abroad  Not specified  
35 94.6 1 2.7    1 2.7  
(8) Period when infection 
happened? 
Yes, known Supposedly  Not known  
3 13.5 29 78.4     5 13.5  
(9) Time of infection 
estimated within 140 days 
before  
diagnosis (recently)? 
yes no  Not specified  
25 67.6 7 18.9    5 13.5  
(10) Source of infection 
known to be HIV infected? 
Yes, known No, not known  Not specified  
3 8.1 12 32.4  22 59.5  
 
$ all questions referring to the past six months before HIV diagnosis. 




sexual intercourse in different situations in the past 
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condoms always during sex with a friend, 43% always at 
the beginning of a sexual relationship. 24% did not use 
condoms consistently when having sex with a person 
they knew to be HIV infected, 43% did use condoms in 
such situations, and 32% did not answer this question. 
We conclude that the majority of the latter did not have or 
did abstain from sexual contacts with partners they knew 
to be infected with HIV (data not shown). 
The reasons why condoms were not used in the 
previous 6 months were related to the use of drugs 
and/or alcohol (5%), problems when using condoms 
(16%), partner’s decision and own obedience (16%), and 
answers covering hope, beliefs and uncertain knowledge 
about HIV transmission risks (48%), the latter including 
16% who said that they did not perceive their sexual 
partner to be at risk for being infected with HIV. The 
statements agreed to in this context of hope, beliefs and 
uncertain HIV-related knowledge were: (i) I believed that 
there was no transmission risk for me; (ii) I hoped that 
nothing would happen; (iii) I assumed that my partner 
was not infected with HIV; and (iv) I did not think that with 






The BED-CEIA as one established method to identify 
recent   HIV  infections  proved  valid  to  identify  incident  
 




Table 4. Different types of unprotected sexual intercourse (no use of condoms) in the past six months before the diagnosis of HIV infection in MSM 
with recently acquired HIV infection (Federal Land of Berlin; Nov 1 2005 - Feb 28 2007) [n=37]. 
 
Types of unprotected sexual 
intercourse (without condom use) and 
number of sexual partners [n = 37] 
unprotected 
(no condom use) 







  … 1 … 2-5 … 6-20 … >20 not spec. 
n % n n n n n n % n % 
Vaginal with partner(s) of unknown HIV 
serostatus 
7 18.9 2 2 1 0 2 24 64.9 6 16.2 
Vaginal with a partner known to be infected 
with HIV 
1 2.7  33 89.2 3 8.1 
Penetrative oral with partner(s) of unknown 
HIV serostatus 
26 70.3 6 9 6 4 1 9 24.3 2 5.5 
Penetrative oral with partner(s) known to 
be infected with HIV 
6 16.2  26 70.3 5 13.5 
Receptive oral with partner(s) of unknown 
HIV serostatus 
6 16.2 2 2 0 1 1 26 70.3 5 13.5 
Receptive oral with a partner known to be 
infected with HIV 
6 16.2  26 70.3 5 13.5 
Penetrative anal with partner(s) of 
unknown HIV serostatus 
19 51.4 8 8 1 1 1 15 40.5 3 8.1 
Penetrative anal with a partner known to be 
infected with HIV 
6 16.2  27 73.0 4 10.8 
Receptive anal with partner(s) of unknown 
HIV serostatus 
19 51.4 8 6 3 0 2 15 40.5 3 8.1 
Receptive anal with a partner known to be 
infected with HIV 




infections, which is not possible in the majority of cases 
during routine HIV diagnosis. Judging descriptively the 
KABP data obtained from a small sample of MSM from 
Berlin, Germany recently infected with HIV, high risk 
behaviour could be observed with regards to protection 
efforts during sexual intercourse especially as to condom 
use. Though 90% of the study participants always 
disposed   on   condoms during the past half year  
(corresponding with the period when they acquired HIV 
infection), 62% used a condom always when having 
anonymous sex. 24% did not use always a condom when 
having sex with a partner they knew to be infected with 
HIV. 32% of the recently HIV-infected patients said that 
they hoped nothing would happen during sexual inter-
course, or they believed or thought actually not to be 
exposed to an HIV transmission risk. 16% assumed that 
the sexual partner was not HIV infected. Interestingly the 
existing knowledge about the trends and dynamics of the 
HIV epidemic in Germany seems relatively good in this 
group of recently infected MSM from Berlin. However, a 
possible advantage through this knowledge with regards 
to preventive behaviour must be disputed. Though 
numerically and methodologically limited, the data sugest 
that almost half of recently HIV infected MSM in this pilot 
study were infected because hope, beliefs, and uncertain 
knowledge on risks for HIV transmission had guided their 
personal decisions on prevention efforts during sexual 
contacts in the past six months. The BED-CEIA could 
confirm with high probability that the HIV infection took 
place within this period. These findings have strong 
implications for amending prevention messages in 
Germany which explicitly intend to address MSM. 
No negative controls (patients who seek medical care 
to test for HIV and revealing negative HIV test results) 
were enrolled at this stage which would have allowed for 
comparative analyses with the recently infected indivi-
duals. This limited design was chosen since in the pilot 
study the readiness of patients with newly diagnosed HIV 
infection to participate in the study was evaluated in the 
first instance. The willingness of persons who test 
negative for HIV to participate in HIV-related research is 
not foreseen as a limitation to the prospected future 
implementation of second generation HIV surveillance in 
Germany. To reduce selection bias of the HIV negative 
controls we choose a matched pairs case-control design 
for the nationwide incidence study. 
The findings furthermore suggest that extension of HIV 
surveillance in Germany by adding continuous KABP 
data collection is feasible and will provide important 
additional data, because real-time data on sexual 
attitudes, behaviour and practices will become conti-
nuously available. Since these data have to be collected 
via treating physicians and after obtaining informed 






KABP data collection should be complemented by an 
additional study arm with negligible selection bias. 
These unbiased HIV recency test results and basic 
demographic data, basic laboratory results (CD4, VL), 
CDC stage, and data about transmission risk category, 
will be obtained from laboratories using surplus serum or 
plasma samples from routine HIV tests. Respective 
samples can be collected for additional anonymous HIV 
testing using the BED-CEIA according to the German 
national Protection against Infection Act (IfSG). These 
data without selection bias can be used to adjust the 
KABP data collected from the clinical study arm for age, 
sex and transmission risks. 
To identify the causes of HIV transmission in recently 
infected individuals KABP data from negative controls 
must become part of the study design. This extended 
design will provide deeper insight into behavioural and 
attitudinal factors which protect from or increase risk for 
acquisition of HIV in different transmission risk categories 
in Germany. Special efforts will have to be made to 
improve contact and response rates of women, hetero-
sexual men and persons originating from HPC who were 
underrepresented in the pilot study. 
To our knowledge this second generation HIV surveil-
lance approach is not yet made use of in other countries 
with concentrated HIV epidemic apart from Switzerland 
where, however, only 34% of patient questionnaires were 
returned and only 32% of these agreed to participate in 
an interview to explore more detailed sexual risk 
behaviours and attitudes towards prevention practices 
(Gebhardt et al., 2007). In Germany a country-wide study 
based upon the results of the pilot study was 
implemented in 2008 and will support HIV prevention with 
highly topical KABP data (Bätzing-Feigenbaum et al., 
2008). The method will be amended in coherence with 





Second generation HIV surveillance combined with HIV 
recency testing proved relevant and feasible to imple-
ment in countries like Germany with a concentrated HIV 
epidemic. Linking data of recently HIV infected persons 
with KABP data collected from the same patients will 
provide useful additional information to support efficient 
and highly topical prevention strategies. The results of 
the pilot study suggest currently existing high risk 
behaviour regarding condom use in recently HIV infected 
MSM in Berlin, Germany. The design of future HIV 
incidence surveillance has to consider special measures 
to avoid selection bias and to improve response rate of 
certain population groups at risk for HIV infection as for 
instance women, heterosexual men and persons with 
origin from HPC. In Germany second generation HIV 
surveillance based on epidemiological core data and 
collection of KABP data was first implemented in 2008. 
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